Boardroom Alpha
Start trial
10-K primary document
ENGN · Annual Report (Form 10-K) · Filed December 22, 2025

Engene Therapeutics Inc — 10-K exhibit

engn-ex10_20b.htm
Engene Therapeutics Inc on Boardroom Alpha
EX-10.20(b)

 

Exhibit 10.20(b)

 

AMENDMENT TO EMPLOYMENT AGREEMENT FOR RONALD H. W. COOPER

This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made by and between enGene USA, Inc. (the “Company”) and Ronald H. W. Cooper (the “Executive”).

WHEREAS, the Company and Executive are parties to an Employment Agreement, effective as of July 22, 2024 (the “Agreement”); and

WHEREAS, the parties desire to amend the Agreement as set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.
Section 7(b)(ii) of the Agreement is hereby deleted in its entirety and restated to read as follows:

 

“(ii) An amount equal to 1.5 times the Annual Target Bonus, payable within forty-five (45) days of Executive’s termination of employment;”

 

2.
General. Except as set forth in this Amendment, the Agreement shall remain in full force and effect according to its terms. The Agreement, as superseded in part and amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter therein. Except as set forth herein, any extension, amendment or other modification to the Agreement or this Amendment must be mutually agreed upon by the parties, in writing and executed by both parties. This Amendment may be signed in counterparts, each of which shall be an original with the same effect as if the signatures were upon the same instrument.

 

IN WITNESS WHEREOF, the parties have executed this Amendment.

ENGENE USA, INC.

By: /s/ Gerald Brunk

Name: Gerald Brunk

Title: Director

Date: October 2, 2025

 

 

EXECUTIVE

 

 

/s/ Ronald H. W. Cooper

Ronald H. W. Cooper

Date: October 2, 2025

1

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer